Last modification: 2024/03/26 https://kinderkrebsinfo.de/doi/e142526


LEaH-Trial (Late Effects after Hodgkin Lymphoma in childhood and adolescence)


Morbus Hodgkin



Problem / Objectives

Cure and survival rates for Hodgkin's disease are over 90 percent and have previously been high. However, the long-term toxicities of the therapies that are usual from 25 to 30 years ago are numerous and sometimes serious, so that survival was and is associated with a reduction in quality of life for some patients. This is mainly due to the traditional extensive use of radiotherapy. But chemotherapy also caused long-term effects due to high cumulative doses of some very effective but toxic drugs.
By regularly recording the late effects over a long period of time, the toxicity of future studies can be reduced by adapting the therapy.
The patients are written to directly; they receive a questionnaire approximately every three years.

Inclusion Criteria

All patients who had been treated within a German-Austrian Morbus Hodgkin trial for children and adolescents

Principal Investigator Dr. med. U. Hennewig, Prof. Dr. med. D. Körholz
URL https://www.ukgm.de/ugm_2/deu/ugi_kih/36685.html


Dr. med. Ulrike Hennewig UKGM Standort Gießen Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen Feulgenstr. 12 35392 Gießen Telefon 0049 (641)985 43844/43421 Fax 0049 (641) 985 43808 ulrike.hennewig@paediat.med.uni-giessen.de

Prof. Dr. med. Dieter Körholz Zentrum für Kinderheilkunde und Jugendmedizin UKGM Standort Gießen - Pädiatrische Hämatologie und Onkologie Feulgenstraße 12 35392 Gießen Telefon +49 (641) 985-43420 Fax +49 (641) 985-43429 dieter.koerholz@paediat.med.uni-giessen.de

Sponsoring Deutsche Kinderkrebsstiftung
Verein zur Förderung krebskranker Kinder Münster e. V.
Jens-Brunken-Stiftung für Leukämie- und Lymphomforschung Varel